Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC13-SPION is a targeted nanotheranostic agent consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with antibodies or ligands specific to Mucin 13 (MUC13). MUC13 is a transmembrane glycoprotein highly overexpressed in various epithelial cancers, particularly pancreatic and colorectal cancers, while showing minimal expression in normal tissues. The SPION core serves as a high-performance contrast agent for T2-weighted magnetic resonance imaging (MRI), while the MUC13 targeting moiety ensures selective accumulation in tumor cells. Beyond diagnostic imaging, these nanoparticles can be utilized for targeted drug delivery or magnetic hyperthermia therapy. Development is primarily academic, notably associated with research into pancreatic cancer detection and treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MUC13-SPION.